Stratifying primary Sjögren's syndrome: killers in the balance?
Simon J Bowman, Benjamin A Fisher, Simon J Bowman, Benjamin A Fisher
Abstract
The article by Seror et al. in Arthritis Research & Therapy reports data from the 15 French patients in the open-label BELISS (Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome, NCT01160666) study of belimumab in primary Sjögren's syndrome. The study identifies that higher baseline levels of natural killer cells in the peripheral blood and salivary glands are associated with non-response to belimumab therapy. Although caution is required given the open-label nature of the trial, this study adds to data already suggesting a role for natural killer cells in primary Sjögren's syndrome and, importantly, indicates a need for therapeutic stratification.
References
- Seror R, Nocturne G, Lazure T, Hendel-Chavez H, Desmoulins F, Belkhir R, et al. Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjogren’s syndrome: results of the BELISS study. Arthritis Res Ther. 2015;17:241. doi: 10.1186/s13075-015-0750-y.
- Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, et al. Efficacy and safety of belimumab in primary Sjögren’s syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis. 2015;74:526–531. doi: 10.1136/annrheumdis-2013-203991.
- Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjögren’s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren’s Syndrome (TRIPSS) Arthritis Rheum. 2004;50:1270–1276. doi: 10.1002/art.20146.
- Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160:233–242. doi: 10.7326/M13-1085.
- Devauchelle-Pensec V, Cagnard N, Pers JO, Youinou P, Saraux A, Chiocchia G. Gene expression profile in the salivary glands of primary Sjögren’s syndrome patients before and after treatment with rituximab. Arthritis Rheum. 2010;62:2262–2271. doi: 10.1002/art.27509.
- Rusakiewicz S, Nocturne G, Lazure T, Semeraro M, Flament C, Caillat-Zucman S, et al. NCR3/NKp30 contributes to pathogenesis in primary Sjogren’s syndrome. Sci Transl Med. 2013;5:195ra96. doi: 10.1126/scitranslmed.3005727.
- Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjögren’s syndrome. Nat Rev Rheumatol. 2013;9:544–556. doi: 10.1038/nrrheum.2013.110.
- Nezos A, Gravani F, Tassidou A, Kapsogeorgou EK, Voulgarelis M, Koutsilieris M, et al. Type I and II interferon signatures in Sjogren’s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren’s related lymphomagenesis. J Autoimmun. 2015;63:47–58. doi: 10.1016/j.jaut.2015.07.002.
- Hall JC, Baer AN, Shah AA, Criswell LA, Shiboski CH, Rosen A, et al. Molecular subsetting of interferon pathways in Sjogren’s syndrome. Arthritis Rheumatol. 2015;67:2437–2446. doi: 10.1002/art.39204.
- Fisher BA, Brown RM, Bowman SJ, Barone F. A review of salivary gland histopathology in primary Sjögren’s syndrome with a focus on its potential as a clinical trials biomarker. Ann Rheum Dis. 2015;74:1645–1650. doi: 10.1136/annrheumdis-2015-207499.
Source: PubMed